drugset

drugset / Trial / NCT00099229

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

NCT00099229 ↗

Phase 3 Completed 320 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

This purpose of this study is to evaluate the safety and efficacy of Licarbazepine for the treatment of manic episodes of bipolar disorder.

Timeline

Start: 2004-11
Primary completion: 2006-08
Completion: 2006-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Licarbazepine	Small molecule	—	—

Indications